VVOS Q1 Call Reinforces Liquidity Dependence; No Signs of Burn Improvement

What happened

Vivos Therapeutics held its Q1 2026 earnings call on May 21, but the transcript revealed no material improvement in the cash burn or financing outlook. The company continues to rely on dilutive equity-linked instruments (PIPEs, warrants, ATM) to fund operations, as FY2025 operating cash outflow exceeded $15M. Q1 revenue likely remained below the level needed to cover sticky clinic-integration overhead, with gross margin near 60% but opex still elevated. The call did not signal a near-term path to cash-flow breakeven, and the heavy warrant overhang from previous raises persists. Management maintained its goal of reaching cash-flow positivity by end-2026, but the lack of concrete burn reduction makes that target increasingly doubtful.

Implication

Holders should monitor Q2 2026 cash burn and filing timeliness closely. A miss on either front (e.g., cash below $1.0M or another delayed 10-Q) would likely trigger a swift re-rating toward the $0.65 bear case. The only path to recovery is two consecutive quarters of opex reduction without further financing overhang – an event we assign less than 15% probability. Re-entry at $0.70 offers a better risk/reward given the heavy supply overhang from warrants exercisable at $1.09.

Thesis delta

The Q1 call provided no evidence that the operating leverage thesis is playing out; opex remains stubbornly high and discounting appears entrenched. This reinforces our 'Potential Sell' rating and pushes the attractive entry point (previously $0.70) closer to materialize. The 15% bull-case probability of a $1.90 outcome should be reduced to ~10% absent a major restructuring.